The year 2022 was a watershed year for the radiopharmaceuticals space with 25 strategic transactions and $527M invested from the VC community. Despite an overall downturn in the biotech market in the 2022-2023 timeframe, the strategic and VC activity within the radiopharmaceutical space has remained relatively strong. Indeed, the average raise for radiopharma sponsors in 2023 was $51M, which eclipsed that of 2022, $38M.
Read MoreThe ability to facilitate the growth and expansion of mammalian cells in vitro has been at the backbone of a wave of therapeutic innovations in the biotech space. Increasingly the know-how, materials, and equipment to harness cells as factories to produce complex proteins for therapeutic uses is being directed toward consumer applications.
Read MoreA growing body of pre-clinical and clinical research has implicated the influence of bacteria on human health which over the last decade led to a flurry of venture capital and biopharma interest. The collection of non-human cells living within the gut, skin, and other tissues (collectively referred to as “microbiota” or the “microbiome”) has a profound influence on maintaining normal physiologic function (homeostasis).
Read MoreA growing body of pre-clinical and clinical research has implicated the influence of bacteria on human health which over the last decade led to a flurry of venture capital and biopharma interest. The collection of non-human cells living within the gut, skin, and other tissues (collectively referred to as “microbiota” or the “microbiome”) has a profound influence on maintaining normal physiologic function (homeostasis).
Read MoreOver the last five years, multiple gene therapies have been approved by regulatory agencies and a bolus of late-stage pipeline assets are approaching the market. As the first few gene therapies realize their potential as transformative treatments for the genetic rare diseases, the space is seen as a crucial part of growth for the biopharmaceutical industry. However, as the first gene therapies began to post early wins, several technical and commercial challenges emerged.
Read MoreOver the last decade, NASH has remained a graveyard for drug development. To date, there are no disease-specific approved therapies on the market. Companies in the dash for a NASH breakthrough may require strategic repositioning to maximize asset value in the near-term. In our latest white paper, Back Bay Life Science Advisors analyzed the opportunities and challenges ahead for companies seeking a NASH breakthrough.
Read MoreCell therapies for cancer, particularly chimeric antigen receptor (CAR)-modified αβ T cells, have rapidly proven their utility. However, as limitations of these therapies have become clearer, interest in alternative approaches has grown. A second generation of companies built on several scientific discoveries is advancing cell therapies of the innate immune system (such as γδ T and NK cells) to address the limitations of CAR T-cell therapies…
Read MoreWith a growing body of pre-clinical and clinical research, the influence of bacteria on human health and disease has emerged from the shadows and into the limelight. The collection of non-human cells living within the gut, skin, and other tissues (collectively referred to as “microbiota” or the “microbiome”), has a profound influence on maintaining normal physiologic function…
Read MoreThe past decade has seen little by way of new treatment for epilepsy, and existing medications can come with significant adverse reactions. Given this, biopharmaceutical companies need to take a different course to improve treatments for people with seizure disorders. For many developers, taking a rare-disease approach may be the answer.
Read MoreIn the world of academic technology development, there is a small pool of academic centers reaping most of the benefit from industry partnering. Back Bay Life Science Advisors analyzed the partnering landscape to offer solutions to increase productivity and investment returns.
Read More